BMO Capital Keeps $73.0 TP On Eli Lilly & Co (LLY), Keeps “Sell” Rating; Leju Holdings Limited (LEJU) SI Increased By 4.74%

November 15, 2017 - By Ellis Scott

Among 20 analysts covering Eli Lilly and Company (NYSE:LLY), 12 have Buy rating, 1 Sell and 7 Hold. Therefore 60% are positive. Eli Lilly and Company has $125 highest and $64 lowest target. $94.42’s average target is 14.46% above currents $82.49 stock price. Eli Lilly and Company had 83 analyst reports since July 23, 2015 according to SRatingsIntel. As per Monday, December 28, the company rating was maintained by Leerink Swann. Jefferies maintained the shares of LLY in report on Friday, June 16 with “Buy” rating. The firm has “Overweight” rating by JP Morgan given on Thursday, September 8. The stock has “Hold” rating by Argus Research on Thursday, April 27. The stock has “Market Perform” rating by BMO Capital Markets on Friday, November 25. On Friday, April 7 the stock rating was maintained by Barclays Capital with “Overweight”. The firm has “Outperform” rating by Leerink Swann given on Thursday, November 12. The rating was maintained by Piper Jaffray on Friday, September 8 with “Buy”. As per Friday, October 27, the company rating was maintained by SunTrust. The stock has “Sell” rating by BMO Capital Markets on Monday, June 5.

Leju Holdings Limited (NYSE:LEJU) had an increase of 4.74% in short interest. LEJU’s SI was 200,900 shares in November as released by FINRA. Its up 4.74% from 191,800 shares previously. With 62,900 avg volume, 3 days are for Leju Holdings Limited (NYSE:LEJU)’s short sellers to cover LEJU’s short positions. The stock increased 10.32% or $0.16 during the last trading session, reaching $1.71. About shares traded. Leju Holdings Ltd (ADR) (NYSE:LEJU) has declined 28.96% since November 15, 2016 and is downtrending. It has underperformed by 45.66% the S&P500.

The stock decreased 0.45% or $0.37 during the last trading session, reaching $82.49. About shares traded. Eli Lilly and Co (NYSE:LLY) has risen 4.70% since November 15, 2016 and is uptrending. It has underperformed by 12.00% the S&P500.

Analysts await Eli Lilly and Co (NYSE:LLY) to report earnings on January, 30. They expect $1.08 EPS, up 13.68% or $0.13 from last year’s $0.95 per share. LLY’s profit will be $1.19 billion for 19.09 P/E if the $1.08 EPS becomes a reality. After $1.05 actual EPS reported by Eli Lilly and Co for the previous quarter, Wall Street now forecasts 2.86% EPS growth.

Eli Lilly and Company is engaged in drug manufacturing business. The company has market cap of $90.83 billion. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. It has a 39.28 P/E ratio. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Since June 9, 2017, it had 0 insider purchases, and 2 insider sales for $1.98 million activity. Barnes Melissa S sold $153,482 worth of stock or 1,900 shares. Shares for $1.83 million were sold by Harrington Michael J on Friday, June 9.

Investors sentiment decreased to 0.9 in 2017 Q2. Its down 0.08, from 0.98 in 2017Q1. It turned negative, as 61 investors sold Eli Lilly and Co shares while 400 reduced holdings. 95 funds opened positions while 320 raised stakes. 823.00 million shares or 0.09% more from 822.25 million shares in 2017Q1 were reported. Jnba Advisors has invested 0.01% in Eli Lilly and Co (NYSE:LLY). Bryn Mawr holds 47,192 shares or 0.23% of its portfolio. Wealthfront has invested 0.03% in Eli Lilly and Co (NYSE:LLY). 4,805 were reported by Mutual Of Omaha Bank & Trust Wealth. Argyle Capital reported 39,932 shares. Woodstock accumulated 0.08% or 4,800 shares. Atwood Palmer has invested 0.01% in Eli Lilly and Co (NYSE:LLY). Ameritas Inv invested in 0.23% or 57,265 shares. Oak Ridge Invs Lc reported 0.57% stake. Jacobus Wealth Management reported 1,650 shares. Columbia Partners L L C Mngmt reported 19,754 shares stake. Moreover, Dnb Asset As has 0% invested in Eli Lilly and Co (NYSE:LLY) for 295,950 shares. Cranbrook Wealth Management Limited Liability Co invested 0% of its portfolio in Eli Lilly and Co (NYSE:LLY). Rand Wealth Ltd Company holds 0.09% or 8,400 shares in its portfolio. Girard Partners, a Pennsylvania-based fund reported 7,033 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :